Denali Therapeutics Inc. (DNLI) Misses Q1 EPS by 8c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q1 EPS of ($0.78), $0.08 worse than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Obsidian Energy Increases Syndicated Credit Facility
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance